{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:29:19Z","timestamp":1789540159205,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40262-018-00732-2","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T04:17:04Z","timestamp":1548303424000},"page":"815-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8020-1934","authenticated-orcid":false,"given":"Stijn W.","family":"van Beek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-7056","authenticated-orcid":false,"given":"Ron J.","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Magis-Escurra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-6445","authenticated-orcid":false,"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"732_CR1","unstructured":"World Health Organization. Global tuberculosis report 2017. \n                    http:\/\/www.who.int\/tb\/publications\/global_report\/en\/\n                    \n                  . Accessed Aug 2018."},{"issue":"8","key":"732_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839\u201354.","journal-title":"Drugs."},{"issue":"9","key":"732_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464\u201373.","journal-title":"J Infect Dis."},{"issue":"2","key":"732_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0950-3528(90)90006-3","volume":"4","author":"GE Griffin","year":"1990","unstructured":"Griffin GE. Malabsorption, malnutrition and HIV disease. Bailliere\u2019s Clin Gastroenterol. 1990;4(2):361\u201373.","journal-title":"Bailliere\u2019s Clin Gastroenterol"},{"issue":"1","key":"732_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pupt.2011.12.001","volume":"25","author":"C Magis-Escurra","year":"2012","unstructured":"Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther. 2012;25(1):83\u20136.","journal-title":"Pulm Pharmacol Ther"},{"issue":"9","key":"732_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S2213-8587(14)70192-5","volume":"2","author":"The Lancet Diabetes Endocrinology","year":"2014","unstructured":"The Lancet Diabetes Endocrinology. Diabetes and tuberculosis: a wake-up call. Lancet Diabetes Endocrinol. 2014;2(9):677.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"732_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0929-6646(11)60055-7","volume":"110","author":"J-T Chang","year":"2011","unstructured":"Chang J-T, Dou H-Y, Yen C-L, Wu Y-H, Huang R-M, Lin H-J, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011;110(6):372\u201381.","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"732_CR8","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","volume":"47","author":"R Jayaram","year":"2003","unstructured":"Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. Pharmacokinetics\u2013pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"732_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","volume":"44","author":"C Magis-Escurra","year":"2014","unstructured":"Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents. 2014;44(3):229\u201334.","journal-title":"Int J Antimicrob Agents."},{"issue":"8","key":"732_CR10","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1128\/AAC.00756-15","volume":"59","author":"MG Sturkenboom","year":"2015","unstructured":"Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, et al. Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrob Agents Chemother. 2015;59(8):4907\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"732_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/FTD.0000000000000093","volume":"36","author":"SE Medellin-Garibay","year":"2014","unstructured":"Medellin-Garibay SE, Correa-Lopez T, Romero-Mendez C, Milan-Segovia RC, Romano-Moreno S. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin. Ther Drug Monit. 2014;36(6):746\u201351.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"732_CR12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Criti Care Med. 2015;191(9):1058\u201365.","journal-title":"Am J Respir Criti Care Med"},{"issue":"10","key":"732_CR13","first-page":"531","volume":"33","author":"JH Proost","year":"1995","unstructured":"Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther. 1995;33(10):531\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"732_CR14","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1128\/AAC.00341-15","volume":"59","author":"A Alsultan","year":"2015","unstructured":"Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother. 2015;59(7):3800\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"732_CR15","unstructured":"InsightRX. The InsightRX platform. San Francisco, CA; 2017. \n                    http:\/\/insight-rx.com\/\n                    \n                  . Accessed Aug 2018."},{"key":"732_CR16","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2016. \n                    https:\/\/www.R-project.org\/\n                    \n                  . Accessed Aug 2018."},{"key":"732_CR17","volume-title":"NONMEM user\u2019s guides (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user\u2019s guides (1989\u20132009). Ellicott City: Icon Development Solutions; 2009."},{"issue":"6","key":"732_CR18","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: Tutorial on pirana, PsN, and Xpose. CPT Pharmacometr Syst Pharmacol. 2013;2(6):e50.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"732_CR19","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. 2011. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500109686%26mid=WC0b01ac058009a3dc\n                    \n                  . Accessed Aug 2018."},{"issue":"7","key":"732_CR20","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.01550-06","volume":"51","author":"R Ruslami","year":"2007","unstructured":"Ruslami R, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"732_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"10","key":"732_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"732_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","volume":"75","author":"W Zhao","year":"2013","unstructured":"Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2013;75(4):1068\u201380.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"732_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"2","key":"732_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometr Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"2","key":"732_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Progr Biomed. 2008;90(2):154\u201366.","journal-title":"Comput Methods Progr Biomed"},{"issue":"4","key":"732_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2307\/2532694","volume":"48","author":"SP Wright","year":"1992","unstructured":"Wright SP. Adjusted P-values for simultaneous inference. Biometrics. 1992;48(4):1005\u201313.","journal-title":"Biometrics."},{"key":"732_CR28","volume-title":"National Health and Nutrition Examination Survey Data","author":"Centers for Disease Control and Prevention","year":"2017","unstructured":"Centers for Disease Control and Prevention, et al. National Health and Nutrition Examination Survey Data. Hyattsville: National Center for Health Statistics; 2017."},{"key":"732_CR29","unstructured":"Keizer RJ. PKPDsim documentation. \n                    http:\/\/www.pkpdsim-docs.com\n                    \n                  . Accessed Aug 2018."},{"issue":"12","key":"732_CR30","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","volume":"41","author":"CA Peloquin","year":"1997","unstructured":"Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997;41(12):2670\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"732_CR31","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1128\/AAC.00461-07","volume":"52","author":"JJ Wilkins","year":"2008","unstructured":"Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother. 2008;52(6):2138\u201348.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"732_CR32","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1128\/AAC.01520-08","volume":"53","author":"S Goutelle","year":"2009","unstructured":"Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009;53(7):2974\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"732_CR33","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1128\/AAC.05792-11","volume":"56","author":"W Smythe","year":"2012","unstructured":"Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother. 2012;56(4):2091\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"732_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jcpt.12016","volume":"38","author":"RC Mil\u00e1n Segovia","year":"2013","unstructured":"Mil\u00e1n Segovia RC, Dominguez Ramirez AM, Jung Cook H, Magana Aquino M, Vigna Perez M, Brundage RC, et al. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. J Clin Pharm Ther. 2013;38(1):56\u201361.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"732_CR35","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1093\/jac\/dkv268","volume":"70","author":"KY Seng","year":"2015","unstructured":"Seng KY, Hee KH, Soon GH, Chew N, Khoo SH, Lee LS. Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. J Antimicrob Chemother. 2015;70(12):3298\u2013306.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"732_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/jcph.643","volume":"56","author":"Y Jing","year":"2016","unstructured":"Jing Y, Zhu LQ, Yang JW, Huang SP, Wang Q, Zhang J. Population pharmacokinetics of rifampicin in chinese patients with pulmonary tuberculosis. J Clin Pharmacol. 2016;56(5):622\u20137.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"732_CR37","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/cpt.202","volume":"98","author":"RM Savic","year":"2015","unstructured":"Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther. 2015;98(6):622\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"732_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bcp.12848","volume":"81","author":"A Schipani","year":"2016","unstructured":"Schipani A, Pertinez H, Mlota R, Molyneux E, Lopez N, Dzinjalamala FK, et al. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. Br J Clin Pharmacol. 2016;81(4):679\u201387.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"732_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.01830-15","volume":"60","author":"MT Chirehwa","year":"2016","unstructured":"Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, et al. Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. Antimicrob Agents Chemother. 2016;60(1):487\u201394.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"732_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/cpt.778","volume":"103","author":"RJ Svensson","year":"2017","unstructured":"Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, et al. A population pharmacokinetic model incorporating saturable pharmacokinetics and auto-induction for high rifampicin doses. Clin Pharmacol Ther. 2017;103(4):674\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"732_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2165\/00003088-200443060-00003","volume":"43","author":"JE Conte","year":"2004","unstructured":"Conte JE, Golden JA, Kipps JE, Lin ET, Zurlinden E. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet. 2004;43(6):395\u2013404.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"732_CR42","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1128\/AAC.05526-11","volume":"56","author":"H McIlleron","year":"2012","unstructured":"McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"732_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy026","volume":"67","author":"EM Svensson","year":"2018","unstructured":"Svensson EM, Svensson RJ, te Brake LHM, Boeree MJ, Heinrich N, Konsten S, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis. 2018;67(1):34\u201341.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"732_CR44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/infdis\/jiy242","volume":"218","author":"RJ Svensson","year":"2018","unstructured":"Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, et al. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. J Infect Dis. 2018;218(6):991\u20139.","journal-title":"J Infect Dis."},{"issue":"1","key":"732_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39\u201349.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"732_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/imj.13412","volume":"47","author":"J Donagher","year":"2017","unstructured":"Donagher J, Martin JH, Barras MA. Individualised medicine: why we need Bayesian dosing. Intern Med J. 2017;47(5):593\u2013600.","journal-title":"Intern Med J"},{"key":"732_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1742-4682-11-39","volume":"11","author":"S Sarem","year":"2014","unstructured":"Sarem S, Li J, Barriere O, Litalien C, Theoret Y, Lapeyraque AL, et al. Bayesian approach for the estimation of cyclosporine area under the curve using limited sampling strategies in pediatric hematopoietic stem cell transplantation. Theor Biol Med Model. 2014;11:39.","journal-title":"Theor Biol Med Model"},{"key":"732_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12353","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, et al. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacometr Syst Pharmacol. 2018. \n                    https:\/\/doi.org\/10.1002\/psp4.12353\n                    \n                  \n                           (Epub 25 Sep 2018).","journal-title":"CPT Pharmacometr Syst Pharmacol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-00732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-00732-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-00732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:14:31Z","timestamp":1579720471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-00732-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-00732-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"23 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for either this study or for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ron J. Keizer is a co-founder and employee of InsightRX. Stijn W. van Beek, Rob ter Heine, Cecile Magis-Escurra, Rob E. Aarnoutse, and Elin M. Svensson declare no conflicts of interest that could have influenced the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocols were approved by the Institutional Review Board of Radboudumc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}